{"id":51619,"date":"2022-12-07T10:00:15","date_gmt":"2022-12-07T10:00:15","guid":{"rendered":"https:\/\/www.etfworld.com\/nl\/?p=51619"},"modified":"2025-05-23T18:17:23","modified_gmt":"2025-05-23T16:17:23","slug":"vaneck-etf-launches-bionic-engineering-etf","status":"publish","type":"post","link":"https:\/\/www.etfworld.com\/nl\/vaneck-etf-launches-bionic-engineering-etf\/","title":{"rendered":"VanEck ETF launches bionic engineering ETF"},"content":{"rendered":"
Asset manager VanEck ETF<\/strong> is listing the VanEck Bionic Engineering UCITS ETF today on both the London Stock Exchange and the German stock exchange Xetra.<\/h5>\n

<\/p>\n

Sign up to our free newsletters<\/a><\/strong><\/p>\n

\n

Martijn Rozemuller, CEO at VanEck Europe<\/strong><\/span><\/p>\n

\n

– Bionics provide solutions for the diseases and disabilities of the ageing population<\/strong><\/p>\n

– The VanEck Bionic Engineering UCITS ETF invests in companies that create solutions for medical implants or artificial body parts<\/strong><\/p>\n

– With the new ETF, VanEck is expanding its range of impact products<\/strong><\/p>\n

The new ETF allows investors to invest in companies from the bionics sector.<\/p>\n

Bionics involves research and development of approaches for developing technical applications based on the model of living systems. The fundamental notion of bionics is the transfer of biology to technology. In the context of healthcare, the term \u201cbionics\u201d represents technologies designed to enhance or restore functions of human body. Fine examples of bionic engineering include prosthetics, bio-printed tissues, replacement organs and body function aids.<\/p>\n

\u201cThe proportion of the elderly population is rising and with it the demand for technical solutions such as hearing and visual aids, pacemakers, artificial joints and the like that improve the quality of life in the old age,\u201d says Martijn Rozemuller, CEO at VanEck Europe<\/strong><\/span>. \u201cAt the same time, increasingly available bionic tools are helping people with chronic diseases such as diabetes or functional disorders.\u201d<\/p>\n

\u201cAs the technology develops, we expect the applications based on functions of the brain and nerve systems to become more prominent. Bionics also have the potential to disrupt healthcare, with innovations like neuroprosthetics enabling treatment of Alzheimer\u2019s and other cognitive diseases aswell as direct brain-to-device communication for paralyzed people.\u201d adds Dominik Schmaus, Product Manager at VanEck Europe<\/strong><\/span>. \u201cBionic Engineering can also be a factor for change in social attitudes. It can reduce stigma and discrimination that people with disability often experience.\u201d<\/p>\n

Pure-play investments in companies that manufacture medical implants<\/p>\n

The VanEck Bionic Engineering UCITS ETF<\/strong><\/span> follows the MVIS\u00ae Global Bionic Healthcare ESG Index<\/strong>, which tracks the performance of companies involved in medical, dental or visual implants, bioprinting, prosthetics or organ and tissue preservation. The accumulating VanEck Bionic Engineering UCITS ETF has a total expense ratio (TER) of 0.55 per cent and is rebalanced quarterly.<\/p>\n

The ETF excludes companies that manufacture implantable or wearable devices or materials used only for cosmetic purposes. The index also excludes companies that have committed very serious violations of social norms, generate sales from controversial weapons or exceed certain thresholds for their sales in various sectors, such as civilian firearms or tobacco<\/p>\n\n\n\n\n\n\n\n\n
ETF<\/span><\/span><\/strong><\/td>\nVanEck Bionic Engineering UCITS ETF<\/strong><\/span><\/td>\n<\/tr>\n
ISIN<\/span><\/span><\/strong><\/td>\nIE0005TF96I9<\/td>\n<\/tr>\n
SEDOL<\/strong><\/td>\nBMTPPH1<\/td>\n<\/tr>\n
Trading Currency<\/strong><\/td>\nGBP<\/td>\n<\/tr>\n
Underlying<\/strong><\/td>\nMVIS\u00ae Global Bionic Healthcare ESG Index<\/strong><\/td>\n<\/tr>\n
Management Fee<\/strong><\/td>\n0.55%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n\n
ETF<\/span><\/span><\/strong><\/td>\nVanEck Bionic Engineering UCITS ETF<\/strong><\/span><\/td>\n<\/tr>\n
ISIN<\/strong><\/td>\nIE0005TF96I9<\/td>\n<\/tr>\n
SEDOL<\/strong><\/td>\nBMTPNY4<\/td>\n<\/tr>\n
Trading Currency<\/strong><\/td>\nUSD<\/td>\n<\/tr>\n
Underlying<\/strong><\/td>\nMVIS\u00ae Global Bionic Healthcare ESG Index<\/strong><\/td>\n<\/tr>\n
Management Fee<\/strong><\/td>\n0.55%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Source: ETFWorld<\/p>\n","protected":false},"excerpt":{"rendered":"

Asset manager VanEck ETF is listing the VanEck Bionic Engineering UCITS ETF today on both the London Stock Exchange and the German stock exchange Xetra.<\/p>\n","protected":false},"author":4,"featured_media":21471,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"telegram_tosend":false,"telegram_tosend_message":"","telegram_tosend_target":0,"footnotes":"","_wpscp_schedule_draft_date":"","_wpscp_schedule_republish_date":"","_wpscppro_advance_schedule":false,"_wpscppro_advance_schedule_date":"","_wpscppro_dont_share_socialmedia":false,"_wpscppro_custom_social_share_image":0,"_facebook_share_type":"","_twitter_share_type":"","_linkedin_share_type":"","_pinterest_share_type":"","_linkedin_share_type_page":"","_instagram_share_type":"","_medium_share_type":"","_threads_share_type":"","_google_business_share_type":"","_selected_social_profile":[],"_wpsp_enable_custom_social_template":false,"_wpsp_social_scheduling":{"enabled":false,"datetime":null,"platforms":[],"status":"template_only","dateOption":"today","timeOption":"now","customDays":"","customHours":"","customDate":"","customTime":"","schedulingType":"absolute"},"_wpsp_active_default_template":true},"categories":[4],"tags":[453,187,238],"class_list":["post-51619","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-etf-europe","tag-martijn-rozemuller","tag-vaneck","tag-vaneck-etf"],"blocksy_meta":{"styles_descriptor":{"styles":{"desktop":"","tablet":"","mobile":""},"google_fonts":[],"version":6}},"_links":{"self":[{"href":"https:\/\/www.etfworld.com\/nl\/wp-json\/wp\/v2\/posts\/51619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.etfworld.com\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.etfworld.com\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.etfworld.com\/nl\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.etfworld.com\/nl\/wp-json\/wp\/v2\/comments?post=51619"}],"version-history":[{"count":1,"href":"https:\/\/www.etfworld.com\/nl\/wp-json\/wp\/v2\/posts\/51619\/revisions"}],"predecessor-version":[{"id":51620,"href":"https:\/\/www.etfworld.com\/nl\/wp-json\/wp\/v2\/posts\/51619\/revisions\/51620"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.etfworld.com\/nl\/wp-json\/wp\/v2\/media\/21471"}],"wp:attachment":[{"href":"https:\/\/www.etfworld.com\/nl\/wp-json\/wp\/v2\/media?parent=51619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.etfworld.com\/nl\/wp-json\/wp\/v2\/categories?post=51619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.etfworld.com\/nl\/wp-json\/wp\/v2\/tags?post=51619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}